Adaptive Biotechnologies Corpor

ADPT

Precision medicineBiotech & pharmaceuticalsHealthcare diagnostics

$25.72vs prev close▼-0.27(-1.04%)

$12.0052W Range$26.16

97% from low

+3.06 (+13.74%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.35%

1M +0.04%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Sell)

Shares decreased, but price appreciation increased portfolio weight.

Shares -11.3% · Market value +1.5% · Weight +0.04%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.09	SELL	ARKG	108,120	$21.80	$2.4M
26.07.08	SELL	ARKG	32,775	$20.16	$660.7K
26.07.07	SELL	ARKG	72,323	$20.82	$1.5M
26.05.14	SELL	ARKG	35,073	$13.18	$462.3K
26.05.13	SELL	ARKG	12,372	$13.13	$162.4K
26.05.07	SELL	ARKG	33,134	$14.69	$486.7K
25.12.22	SELL	ARKG	35,555	$17.41	$619.0K
25.12.18	SELL	ARKG	35,311	$16.50	$582.6K
25.12.10	SELL	ARKG	35,379	$15.74	$556.9K
25.12.09	SELL	ARKG	90,807	$14.86	$1.3M
25.12.08	SELL	ARKG	108,578	$14.95	$1.6M
25.12.05	SELL	ARKG	195,141	$14.75	$2.9M
25.11.05	SELL	ARKG	87,072	$17.59	$1.5M
25.11.04	SELL	ARKG	25,846	$16.92	$437.3K
25.11.03	SELL	ARKG	46,710	$17.34	$810.0K

07.09SELL

108,120

ARKGClose$21.80Est. total$2.4M

07.08SELL

32,775

ARKGClose$20.16Est. total$660.7K

07.07SELL

72,323

ARKGClose$20.82Est. total$1.5M

05.14SELL

35,073

ARKGClose$13.18Est. total$462.3K

05.13SELL

12,372

ARKGClose$13.13Est. total$162.4K

05.07SELL

33,134

ARKGClose$14.69Est. total$486.7K

12.22SELL

35,555

ARKGClose$17.41Est. total$619.0K

12.18SELL

35,311

ARKGClose$16.50Est. total$582.6K

12.10SELL

35,379

ARKGClose$15.74Est. total$556.9K

12.09SELL

90,807

ARKGClose$14.86Est. total$1.3M

12.08SELL

108,578

ARKGClose$14.95Est. total$1.6M

12.05SELL

195,141

ARKGClose$14.75Est. total$2.9M

11.05SELL

87,072

ARKGClose$17.59Est. total$1.5M

11.04SELL

25,846

ARKGClose$16.92Est. total$437.3K

11.03SELL

46,710

ARKGClose$17.34Est. total$810.0K

1 / 8

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

3 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

1,770,358

Portfolio Weight

0.35%

in ETF 2.63%

Est. Value

$44M

30D Net

-$3M

Ray DalioBridgewater Associates

Increased

265,491

Portfolio Weight

0.02%

Est. Value

$4M

vs Prev Quarter

+76% (151K→265K)

Andreas HalvorsenViking Global Investors

Maintained

29,993,708

Portfolio Weight

1.29%

Est. Value

$487M

vs Prev Quarter

Maintained

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$25.07

vs Current ▼ -3.5% downside

Current$25.99

Low ~ High$21.00 ~ $28.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Piper Sandler

Overweight

$27.50

+5.81%

—

Maintain

2026-08-04

Morgan Stanley

Equal-Weight

$22.00

-15.35%

—

Maintain

2026-07-30

TD Cowen

Buy

$28.00

+7.73%

—

Maintain

2026-07-30

Guggenheim

Buy

$25.00

-3.81%

—

Maintain

2026-07-30

BTIG

Buy

$25.00

-3.81%

—

Maintain

2026-07-30

1 / 4

Avg Target

$25.07

vs Current ▼ -3.5% downside

Strong Buy

8 analysts

Strong Buy 2Buy 5Hold 1

Low $21.00

Current $25.99

High $28.00

Firm	Position	Target	Upside	Close	Action	Date
Piper Sandler	Overweight	$27.50	+5.81%	—	Maintain	26.08.04
Morgan Stanley	Equal-Weight	$22.00	-15.35%	—	Maintain	26.07.30
TD Cowen	Buy	$28.00	+7.73%	—	Maintain	26.07.30
Guggenheim	Buy	$25.00	-3.81%	—	Maintain	26.07.30
BTIG	Buy	$25.00	-3.81%	—	Maintain	26.07.30

1 / 4

Price Information

Previous Close$25.44

Open$25.37

Day Range$24.93 - $26.03

52-Week Range$12.00 - $26.16

1-Year Change105.13%

Trading Volume

Volume1,815,950

Avg Volume (3mo)2,986,330

Valuation

Market Cap4.1B

Book Value$0.90

Shares Outstanding159,595,842

Financials

Revenue (TTM)308.1M

Net Income-63,854,000

EPS$-0.40

EBITDA-21,327,000

Profitability

P/E Ratio-

P/B Ratio28.94

Return on Equity (ROE)-38.76%

Return on Assets (ROA)-4.12%

Profit Margin-20.73%

EV/EBITDA-197.96

Beta2.09

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)69.51

Company Overview

Adaptive Biotechnologies Corporation is a commercial-stage company that has developed an immune medicine platform to diagnose and treat diseases. Their main offerings include an immunosequencing platform and the clonoSEQ diagnostic test for monitoring cancer cells, serving life sciences research, clinical diagnostics, and drug discovery. The company holds a significant position in leveraging immune system data for medical advancements.

P/B

28.94

High valuation

ROE

-38.8%

Persistent loss

Beta

2.09

Extreme volatility

RSI(14)

69.5

Neutral zone

AI-generated summary. Not investment advice.

Adaptive Biotechnologies Corpor

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks